Epistem's Biomarker Division Gains GCLP Accreditation
Epistem plc has announced that their Biomarker Division has been awarded Good Clinical Laboratory Practice (GCLP) accreditation status. The Biomarker Division conducts gene expression analysis to support clinical drug development programs within pharmaceutical and biotechnology organisations, with an increasing focus on providing valuable biomarker information that can be used in diagnostic applications.
For use in tissue and sample preparation, Epistem has developed a proprietary cDNA amplification technique which enables gene expression information to be provided from very small (or degraded) biological samples such as formalin-fixed, paraffin-embedded (FFPE) tissue, laser captured microdissected (LCM) samples, single plucked hairs, fractionated blood cells and pinch biopsies. Epistem also provides 'off the shelf' and proprietary panels of biomarkers targeting known oncology and disease specific biological pathways. Epistem has pioneered a technique to provide and interpret gene expression information from single plucked hairs, working with drug development companies globally to support biomarker programmes which translate from preclinical proof of concept to clinical phases.
GCLP accreditation now enables Epistem to support the later stage clinical phases of drug development assuring customers that all studies will be conducted to GCLP quality standards set by the British Association of Research Quality Assurance. GCLP status demonstrates that the Biomarker Division operates to a standard that assures the reliability, quality and integrity of the work and results generated.
Most read news
Topics
Organizations
Other news from the department politics & laws
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Medicago completes cGMP qualification of its manufacturing facility
Study finds potential new biomarker for cancer patient prognosis
The "profile" of neon becomes more exact - PTB researchers determine the polarizability of neon with extreme accuracy - their procedure helps to revise theoretical models and is also of use for other elements
Domestic cat genome sequenced
SPECTRO Reaches Milestone with Shipment of 40,000th Instrument
Cells bulge to squeeze through barriers
Johnson & Johnson Nordic AB Acquires Amic - Gains Access to In Vitro Diagnostic Technologies in Development for Use in Point-of-Care Settings
ATLAS Biolabs fulfills the DIN EN ISO 13485:2003 + AC: 2009 standard for designing and manufacturing medical devices
Right under your nose: A more convenient way to diagnose Alzheimer's disease - Certain proteins in nasal discharge can indicate the onset and progression of Alzheimer's, providing an avenue for early detection
Wiley InterScience Launches the Analytical Sciences Backfile Collection
A swallowable test to detect pre-cancerous Barrett's esophagus